Recent publications

Publications 2022

• Balcar L, Semmler G, Oberkofler H, Zandanell S, Strasser M, Datz L, Niederseer D, Feldman A, Stickel F, Datz C, Paulweber B, Aigner E
  PNPLA3 is the dominant SNP linked to liver disease severity at time of first referral to a tertiary center.
  Dig. Liver Dis.2022; 54(1):84-90
• Balcar L, Tonon M, Semmler G, Calvino V, Hartl L, Incicco S, Jachs M, Bauer D, Hofer BS, Gambino CG, Accetta A, Brocca A, Trauner M, Mandorfer M, Piano S, Reiberger T; Baveno Cooperation: an EASL consortium. Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. JHEP Rep. 2022 Jun 3;4(8):100513.
• Balcar L, Scheiner B, Urheu M, Weinberger P, Paternostro R, Simbrunner B, Hartl L, Jachs M, Bauer D, Semmler G, Willheim C, Pinter M, Ferenci P, Trauner M, Reiberger T, Stättermayer AF, Mandorfer M. Alpha-1 antitrypsin Pi∗Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease. JHEP Rep. 2022 Aug 20;4(11):100562. 
• Bauer D, Kozbial K, Schwabl P, Chromy D, Simbrunner B, Stättermayer AF, Pinter M, Steindl-Munda P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Angiopoietin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension. Dig Liver Dis. 2022 Apr 3:S1590-8658(22)00204-3
• Bauer DJ, Matic V, Mare R, Maiocchi L, Chromy D, Müllner-Bucsics T, Mandorfer M, Mustapic S, Sporea I, Ferraioli G, Grgurevic I, Reiberger T. Point Shear Wave Elastography by ElastPQ for Fibrosis Screening in Patients with NAFLD: A Prospective, Multicenter Comparison to Vibration-Controlled Elastography. Ultraschall Med. 2022 Feb 28.
• Brusilovskaya K, Simbrunner B, Lee S, Eichelberger B, Bauer D, Zinober K, Schwabl P, Mandorfer M, Panzer S, Reiberger T, Gremmel T. Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis. Platelets. 2022 Jan 4:1-8.
• Bucsics T, Lampichler K, Vierziger C, Schoder M, Wolf F, Bauer D, Simbrunner B, Hartl L, Jachs M, Scheiner B, Trauner M, Gruenberger T, Karnel F, Mandorfer M, Reiberger T. Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis. Dig Dis Sci. 2022 Dec;67(12):5693-5703
• Burghart L, Halilbasic E, Schwabl P, Simbrunner B, Stättermayer AF, Petrenko O, Scheiner B, Bauer D, Pinter M, Boztug K, Mandorfer M, Trauner M, Reiberger T. Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. J Gastroenterol. 2022 Feb;57(2):99-110
• Busslinger GA. Barrett's esophagus stages: their correlation with SBS17-associated DNA mutations and the identification of histological marker genes. Mol Cell Oncol. 2022 Jan 22;9(1):2026559.
• Chromy D, Bauer DJM, Simbrunner B, Jachs M, Hartl L, Schwabl P, Schwarz C, Rieger A, Grabmeier-Pfistershammer K, Trauner M, Ferenci P, Mandorfer M, Gschwantler M, Reiberger T. The 'Viennese epidemic' of acute HCV in the era of direct-acting antivirals. J Viral Hepat. 2022  May;29(5):385-394 
• Zessner-Spitzenberg J, Waldmann E, Ferlitsch M. [Quality Assurance of Screening Colonoscopy in Austria and Europe]. J Gastroenterol Hepatol Erkrank. 2022 Oct 27:1-8.
• Fuchs CD, Radun R, Dixon ED, Mlitz V, Timelthaler G, Halilbasic E, Herac M, Jonker JW, Ronda OAHO, Tardelli M, Haemmerle G, Zimmermann R, Scharnagl H, Stojakovic T, Verkade HJ, Trauner M. Hepatocyte-specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin-like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice. Hepatology. 2022 Jan;75(1):125-139  
• Fuchs CD, Dixon ED, Hendrikx T, Mlitz V, Wahlström A, Ståhlman M, Scharnagl H, Stojakovic T, Binder CJ, Marschall HU, Trauner M. Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2-/- mouse model of sclerosing cholangitis via immunomodulatory effects. Hepatol Commun. 2022  Sep;6(9):2368-2378
• Fuchs CD, Trauner M.
  Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology.
  Nat Rev Gastroenterol Hepatol. 2022 Feb 14. doi: 10.1038/s41575-021-00566-7. 
• Sterniste G, Hammer K, Memaran N, Huber WD, Hammer J. Significance of validated symptom assessment versus breath testing for malabsorption after lactose load in children. Eur J Gastroenterol Hepatol. 2022 Mar 1;34(3):274-280.
• Hartl L, Haslinger K, Angerer M, Jachs M, Simbrunner B, Bauer DJM, Semmler G, Scheiner B, Eigenbauer E, Strassl R, Breuer M, Kimberger O, Laxar D, Trauner M, Mandorfer M, Reiberger T. Age-adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID-19 patients. Liver Int. 2022 Jun;42(6):1297-1307 
• Hartl L, Haslinger K, Angerer M, Semmler G, Schneeweiss-Gleixner M, Jachs M, Simbrunner B, Bauer DJM, Eigenbauer E, Strassl R, Breuer M, Kimberger O, Laxar D, Lampichler K, Halilbasic E, Stättermayer AF, Ba-Ssalamah A, Mandorfer M, Scheiner B, Reiberger T, Trauner M. Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in chronic liver disease patients. Hepatology. 2022 May 21;10.1002/hep.32582
• Hartl L, Jachs M, Bauer D, Simbrunner B, Chromy D, Binter T, Steininger L, Schwarz C, Schwarz M, Burghart L, Strassl R, Trauner M, Gschwantler M, Mandorfer M, Reiberger T. HCV hotline facilitates Hepatitis C elimination during the COVID-19 pandemic. J Viral Hepat. 2022 Dec;29(12):1062-1072
• Hartl L, Tatscher E, Weiss M, Balcar L, Strassl R, Jachs M, Mandorfer M, Soliman T, Stadlbauer V, Schemmer P, Berlakovich G, Tilg H, Schneeberger S, Trauner M, Fickert P, Reiberger T, Graziadei I. The impact of COVID-19 on liver transplantation programs in Austria. Wien Klin Wochenschr. 2022 Nov 11:1-8.
• Hofer BS, Simbrunner B, Bauer DJM, Paternostro R, Schwabl P, Scheiner B, Semmler G, Hartl L, Jachs M, Datterl B, Staettermayer AF, Trauner M, Mandorfer M, Reiberger T. Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis. Hepatol Commun. 2022 Sep;6(9):2569-2580
• Jachs M, Hartl L, Bauer D, Simbrunner B, Stättermayer AF, Strassl R, Trauner M, Mandorfer M, Reiberger T. Long-Term Outcome of HBV-Infected Patients with Clinically Significant Portal Hypertension Achieving Viral Suppression. J Pers Med. 2022 Feb 8;12(2):239.  
• Jachs M, Schwarz C, Panzer M, Binter T, Aberle SW, Hartl L, Dax K, Aigner E, Stättermayer AF, Munda P, Graziadei I, Holzmann H, Trauner M, Zoller H, Gschwantler M, Mandorfer M, Reiberger T, Ferenci P. Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-Results of A "real world" Study. Aliment Pharmacol Ther. 2022 Jul;56(1):144-154 
• Jachs M, Hartl L, Simbrunner B, Bauer D, Paternostro R, Balcar L, Hofer B, Pfisterer N, Schwarz M, Scheiner B, Stättermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T. Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis. Clin Gastroenterol Hepatol. 2022 Jul 14:S1542-3565(22)00642-5. 
• Jachs M, Hartl L, Simbrunner B, Bauer D, Paternostro R, Scheiner B, Balcar L, Semmler G, Stättermayer AF, Pinter M, Quehenberger P, Trauner M, Reiberger T, Mandorfer M. The sequential application of Baveno VII criteria and VITRO score improves diagnosis of clinically significant portal hypertension. Clin Gastroenterol Hepatol. 2022 Oct 13:S1542-3565(22)00957-0.
• Königshofer P, Hofer BS, Brusilovskaya K, Simbrunner B, Petrenko O, Wöran K, Herac M, Stift J, Lampichler K, Timelthaler G, Bauer D, Hartl L, Robl B, Sibila M, Podesser BK, Oberhuber G, Schwabl P, Mandorfer M, Trauner M, Reiberger T. Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. Hepatology. 2022 Mar;75(3):610-622.
• Kutschera M, Ritschl V, Reichardt B, Stamm T, Kiener H, Maier H, Reinisch W, Benka B, Novacek G. Impact of COVID-19 Pandemic on Initiation of Immunosuppressive Treatment in Immune-Mediated Inflammatory Diseases in Austria: A Nationwide Retrospective Study. J Clin Med. 2022 Sep 9;11(18):5308.
• Thaler J, Lisman T, Quehenberger P, Hell L, Schwabl P, Scheiner B, Bucsics T, Nieuwland R, Ay C, Trauner M, Pabinger I, Reiberger T, Mandorfer M. Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. Thromb Haemost. 2022 Mar;122(3):353-362.   
• Bastati N, Beer L, Ba-Ssalamah A, Poetter-Lang S, Ambros R, Kristic A, Lauber D, Pomej K, Binter T, Simbrunner B, Semmler G, Balcar L, Bican Y, Hodge JC, Wrba T, Trauner M, Reiberger T, Mandorfer M. Gadoxetic Acid-enhanced MRI-derived Functional Liver Imaging Score (FLIS) and Spleen Diameter Predict Outcomes in ACLD. J Hepatol. 2022 May 4:S0168-8278(22)00268-9
• Mandorfer M, Scheiner B, Lisman T. On coagulation in advanced chronic liver disease and the origin of freshwater eels. J Hepatol. 2022 Jun 7:S0168-8278(22)00350-6. 
• Paternostro R, Becker J, Hofer BS, Panagl V, Schiffke H, Simbrunner B, Semmler G, Schwabl P, Scheiner B, Bucsics T, Bauer D, Binter T, Trauner M, Mandorfer M, Reiberger T. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. Dig Liver Dis. 2022 Apr;54(4):500-508.  
• Paternostro R, Kwanten WJ, Reiberger T. Portal hypertension is a key determinant of the risk for liver-related events in non-alcoholic fatty liver disease. J Hepatol. 2022 Sep 4:S0168-8278(22)03062-8
• Pinter M, Pinato DJ, Ramadori P, Heikenwalder M. NASH and hepatocellular carcinoma: immunology and immunotherapy. Clin Cancer Res. 2022 Sep 27:CCR-21-1258.
• Samadaei M, Senfter D, Madlener S, Uranowska K, Hafner C, Trauner M, Rohr-Udilova N, Pinter M. Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma. J Cell Biochem. 2022 Oct;123(10):1663-1673.
• Pinter M, Pinato DJ, Ramadori P, Heikenwalder M. NASH and hepatocellular carcinoma: immunology and immunotherapy. Clin Cancer Res. 2022 Sep 27:CCR-21-1258.  
• Samadaei M, Senfter D, Madlener S, Uranowska K, Hafner C, Trauner M, Rohr-Udilova N, Pinter M. Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma. J Cell Biochem. 2022 Oct;123(10):1663-1673.
• Pokryszka J, Reinisch S, Primas C, Novacek G, Reinisch W. Induction Efficacy of Upadacitinib in Therapy-Refractory Crohn's Disease: A Retrospective Case Series. Clin Gastroenterol Hepatol. 2022 Jan 13:S1542-3565(22)00027-1
• Pokryszka J, Wagner A, Wiedermann U, Tobudic S, Herkner H, Winkler S, Brehovsky S, Reinisch W, Novacek G. Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases. Vaccines (Basel). 2022 May 11;10(5):759. 
• Pomej K, Scheiner B, Balcar L, Nussbaumer RJ, Weinzierl J, Paternostro R, Simbrunner B, Bauer D, Pereyra D, Starlinger P, Stättermayer AF, Pinter M, Trauner M, Quehenberger P, Reiberger T, Mandorfer M. Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease. Dig Liver Dis. 2022 Jul 21:S1590-8658(22)00549-7
• Primas C, Reinisch W, Panetta JC, Eser A, Mould DR, Dervieux T. Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases. J Clin Med. 2022 Jun 9;11(12):3316.
• Reiniš J, Petrenko O, Simbrunner B, Hofer BS, Schepis F, Scoppettuolo M, Saltini D, Indulti F, Guasconi T, Albillos A, Téllez L, Villanueva C, Brujats A, Garcia-Pagan JC, Perez-Campuzano V, Hernández-Gea V, Rautou PE, Moga L, Vanwolleghem T, Kwanten WJ, Francque S, Trebicka J, Gu W, Ferstl PG, Gluud LL, Bendtsen F, Møller S, Kubicek S, Mandorfer M, Reiberger T. Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis. J Hepatol. 2022 Sep 21:S0168-8278(22)03119-1
• Reinisch W, Hébuterne X, Buisson A, Schreiber S, Desreumaux P, Primas C, Paillarse JM, Chevalier G, Bonny C. Safety, pharmacokinetic, and pharmacodynamic study of sibofimloc, a novel FimH blocker in patients with active Crohn's disease. J Gastroenterol Hepatol. 2022 May;37(5):832-840
• Reinisch W, Serone A, Hébuterne X, Kühbacher T, Kłopocka M, Roblin X, Brodbeck J, Etchevers K, Galien R, Grant E, Tasset C, Yoon OK, Zaboli S, Vermeire S. Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's disease and is responsive to filgotinib. Tissue Barriers. 2022 Jun 28:2088961.
• Narula N, Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W. The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's Disease. Inflamm Bowel Dis. 2022 Jun 28:izac130.   
• Hellstrom WJG, Dolhain RJEM, Ritter TE, Watkins TR, Arterburn SJ, Dekkers G, Gillen A, Tonussi C, Gilles L, Oortwijn A, Van Beneden K, de Vries DE, Sikka SC, Vanderschueren D, Reinisch W. MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases. Adv Ther.2022 Jul;39(7):3403-3422.
• Remetic J, Ghallab A, Hobloss Z, Brackhagen L, Hassan R, Myllys M, Radun R, Mlitz V, Zhu C, Baumgartner M, Schrottmaier WC, Mussbacher M, Timelthaler G, Scharnagl H, Stojakovic T, Assinger A, Fuchs CD, Hengstler JG, Trauner M. Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance. Hepatology. 2022 May;75(5):1095-1109. 
• Narula N, Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W. Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease. Am J Gastroenterol. 2022 Jul 1;117(7):1106-1117
• Ricciuto A, Rauter I, McGovern DPB, Mader RM, Reinisch W. Precision Medicine in Inflammatory Bowel Diseases: Challenges and Considerations for the Path Forward. Gastroenterology. 2022 Mar 9:S0016-5085(22)00234-7. 
• Narula N, Merat S, Liu D, Pugatch D, Reinisch W. Time to endorse a sensitive method for scoring endoscopic activity of ulcerative colitis in clinical research. J Crohns Colitis. 2022 Aug 24:jjac120.
• Narula N, Wong ECL, Marshall JK, Jairath V, Dulai PS, Reinisch W. Long-term Outcomes of Early Versus Delayed Responders to Vedolizumab and Adalimumab: A Post-hoc Analysis of VARSITY. Am J Gastroenterol. 2022 Sep
• Narula N, Wong ECL, Aruljothy A, Dulai PS, Colombel JF, Marshall JK, Ferrante M, Reinisch W. Baseline Patient-reported Symptoms Less Predictive Than MM-SES-CD for Endoscopic Remission in Crohn's Disease. J Clin Gastroenterol. 2022 Oct 11.
• Scheiner B, Balcar L, Nussbaumer RJ, Weinzierl J, Paternostro R, Simbrunner B, Hartl L, Jachs M, Bauer D, Stättermayer AF, Semmler G, Pinter M, Ay C, Quehenberger P, Trauner M, Reiberger T, Lisman T, Mandorfer M. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.J Hepatol. 2022 Jan 20:S0168-8278(22)00009-5. 
• Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J, Fründt TW, Stadler M, Heinzl H, Shmanko K, Spahn S, Radu P, Siebenhüner AR, Mertens JC, Rahbari NN, Kütting F, Waldschmidt DT, Ebert MP, Teufel A, De Dosso S, Pinato DJ, Pressiani T, Meischl T, Balcar L, Müller C, Mandorfer M, Reiberger T, Trauner M, Personeni N, Rimassa L, Bitzer M, Trojan J, Weinmann A, Wege H, Dufour JF, Peck-Radosavljevic M, Vogel A, Pinter M. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. 2022 Feb;76(2):353-363. 
• Semmler G, Meyer EL, Mandorfer M. De novo HCC risk stratification after HCV cure: All roads lead to Rome? J Hepatol. 2022 Jul 20:S0168-8278(22)02944-0
• Wöran K, Semmler G, Jachs M, Simbrunner B, Bauer DJM, Binter T, Pomej K, Stättermayer AF, Schwabl P, Bucsics T, Paternostro R, Lampichler K, Pinter M, Trauner M, Mandorfer M, Stift J, Reiberger T, Scheiner B. Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. Clin Gastroenterol Hepatol. 2022 Feb;20(2):e251-e266.  
• Semmler G, Lindorfer A, Schaefer B, Bartl S, Hametner-Schreil S, Gensluckner S, Balcar L, Pomej K, Lampichler K, Trauner M, Aigner E, Datz C, Zoller H, Hofer H, Schoefl R, Mandorfer M, Reiberger T, Scheiner B. Outcome of Budd-Chiari Syndrome (BCS) patients treated with direct oral anticoagulants (DOACs) - an Austrian multicenter study. Clin Gastroenterol Hepatol. 2022 May 6:S1542-3565(22)00449-9 
• Semmler G, Wernly S, Wernly B, Datz C. Nomenclature Dilemma of MAFLD Across the Globe: Our Prism to Understand Metabolic Dysfunction and Cardiovascular Risk in MAFLD. Clin Gastroenterol Hepatol. 2022 Jun 11:S1542-3565(22)00562-6.
• Semmler G, Lens S, Meyer EL, Baiges A, Alvarado-Tapias E, Llop E, Tellez L, Schwabl P, Mauro E, Escudé L, Díez C, Ibañez-Samaniego L, Puente Á, Ignacio Fortea J, Abadía M, Zanetto A, Conthe A, Hernandez-Évole H, Sofia Luzko Scheid I, Jia J, Yoshiji H, Francque SM, Tsochatzis EA, Paolo Russo F, Crespo G, Forns X, Bañares R, Villanueva C, Hernández-Gea V, Reiberger T, Bosch J, García-Pagán JC, Mandorfer M; A study by the Baveno Cooperation: an EASL consortium. Non-invasive tests for clinically significant portal hypertension after HCV cure. J Hepatol. 2022 Dec;77(6):1573-1585.
• Schwabl P, Seeland BA, Riedl F, Schubert TL, Königshofer P, Brusilovskaya K, Petrenko O, Hofer B, Schiefer AI, Trauner M, Peck-Radosavljevic M, Reiberger T. Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension. Adv Med Sci. 2022 Mar;67(1):154-162.  
• Semmler G, Meyer EL, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Bauer D, Chromy D, Simbrunner B, Scheiner B, Stättermayer AF, Pinter M, Schöfl R, Russo FP, Greenfield H, Schwarz M, Schwarz C, Gschwantler M, Alonso López S, Manzano ML, Ahumada A, Bañares R, Pons M, Rodríguez-Tajes S, Genescà J, Lens S, Trauner M, Ferenci P, Reiberger T, Mandorfer M. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol. 2022 Apr;76(4):812-821 
• Simbrunner B, Villesen IF, Königshofer P, Scheiner B, Bauer D, Paternostro R, Schwabl P, Timelthaler G, Ramazanova D, Wöran K, Stift J, Eigenbauer E, Stättermayer AF, Marculescu R, Pinter M, Møller S, Trauner M, Karsdal M, Leeming DJ, Reiberger T, Mandorfer M. Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease. Liver Int. 2022 42(11):2501-2512 
• Staufer K, Huber-Schönauer U, Strebinger G, Pimingstorfer P, Suesse S, Scherzer TM, Paulweber B, Ferenci P, Stimpfl T, Yegles M, Datz C, Trauner M. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J Hepatol. 2022 May 20:S0168-8278(22)00316-6. 
• Staufer K, Mangal B, Trauner M. Detection of unreported alcohol consumption in fatty liver disease. J Hepatol. 2022 Oct 26:S0168-8278(22)03153-1.
• Schneeweiss-Gleixner M, Filik Y, Stefanzl G, Berger D, Sadovnik I, Bauer K, Smiljkovic D, Eisenwort G, Witzeneder N, Greiner G, Hoermann G, Schiefer AI, Schwaab J, Jawhar M, Reiter A, Sperr WR, Arock M, Valent P, Gleixner KV. CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells. Cancers (Basel). 2022 Jun 23;14(13):3070. 
• Trauner M, Bowlus CL, Gulamhusein A, Hameed B, Caldwell SH, Shiffman ML, Landis C, Muir AJ, Billin A, Xu J, Liu X, Lu X, Chung C, Myers RP, Kowdley KV. Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC. Clin Gastroenterol Hepatol. 2022 Aug 4:S1542-3565(22)00720-0.
• Wewalka M, Schneeweiss M, Haselwanter P, Schneeweiss B, Zauner C. Age-dependent differences in energy metabolism in the acute phase of critical illness. Nutrition. 2022 Sep;101:111684. 
• Weilguny-Schöfl G, Dolak W, Fellinghauer M, Schober T, Schöfl R. [Health status of endoscopy personnel in Austria]. Z Gastroenterol. 2022 Nov;60(11):1625-1634.